None listed
Conditions
Interventions
None listed
Sponsors
The Catholic University of Korea, Bucheon St. Mary's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: •male or female = 19 years old •Diagnosed type 2 diabetes mellitus • Patients who are scheduled to receive or have initiated the administration of SoliquaPen (10-40) and SoliquaPen (30-60) in accordance with the approved indications, based on the medical judgment of the investigator after the contract with the research institution • Patients who have understood the contents of the informed consent form for study participant data utilization, and voluntarily signed and dated the consent form.
Exclusion criteria
Exclusion criteria: • Patients treated with SoliquaPen (10-40) and SoliquaPen (30-60) outside the conditions of the approved indications in South Korea. • Patients who have previously used SoliquaPen (insulin glargine & lixisenatide) before the contract with the research institution. • Patients who were already using SoliquaPen (insulin glargine & lixisenatide) at the time of contract with the research institution. • Patients with contraindications to the treatment with SoliquaPen (10-40) and SoliquaPen (30-60) as specified in the approved indications: - Patients hypersensitive to the main ingredients or other components of this drug. - Patients with Type 1 diabetes or diabetic ketoacidosis. • Pregnant, lactating, or women planning to become pregnant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Significant Adverse Events | — |
Secondary
| Measure | Time frame |
|---|---|
| • Glycosylated Hemoglobin Test (HbA1c(%));Fasting plasma glucose;2h-post prandial glucose;body weight | — |
Countries
Korea, Republic of
Contacts
Public ContactSang Soo Kim
Pusan National University Hospital
Outcome results
None listed